SOPHiA GENETICS SA logo

SOPHiA GENETICS SANASDAQ: SOPH

Profile

Sector:

Healthcare

Country:

Switzerland

IPO:

23 July 2021

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$210.61 M
-78%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-48%vs. 3y high
54%vs. sector
-87%vs. 3y high
51%vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$3.17-$0.10(-3.06%)

Dividend

No data over the past 3 years
$15.85 M$18.08 M
$15.85 M-$18.44 M

Analysts recommendations

Institutional Ownership

SOPH Latest News

SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
seekingalpha.com05 November 2024 Sentiment: NEUTRAL

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Operator Good morning. My name is Nicole [ph] and I will be your conference operator today.

SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
prnewswire.com05 November 2024 Sentiment: POSITIVE

BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO.

SOPHiA GENETICS Reports Third Quarter 2024 Results
prnewswire.com05 November 2024 Sentiment: POSITIVE

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Quarter  2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72.5% in the prior year period, respectively Operating loss was $15.4 million on a reported basis and $10.6 million on an adjusted basis, representing year-over-year improvements of 7.1% and 10.4%, respectively Cash burn was $9.6 million, representing a year-over-year improvement of 39.1% The company reiterates full-year guidance, including revenue between $65 million and $67 million, adjusted gross margin of 72.0% to 72.5%, and adjusted operating loss between $45 million and $50 million "Record analysis volume drove a reacceleration of Clinical growth across most key geographies in Q3, with volume increasing 16% year-over-year, offset by expected softness in BioPharma," said Jurgi Camblong, PhD.

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
prnewswire.com22 October 2024 Sentiment: POSITIVE

BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
prnewswire.com14 September 2024 Sentiment: POSITIVE

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024.

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
prnewswire.com12 September 2024 Sentiment: POSITIVE

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
prnewswire.com12 September 2024 Sentiment: POSITIVE

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY.

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
prnewswire.com05 September 2024 Sentiment: POSITIVE

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio.

What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
zacks.com09 August 2024 Sentiment: POSITIVE

SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SOPHiA GENETICS Reports Second Quarter 2024 Results
prnewswire.com06 August 2024 Sentiment: POSITIVE

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter  2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-over-year Gross margins were 68.2% on a reported basis and 73.2% on an adjusted basis, up from 66.7% and 70.0% in the prior year period, respectively Operating loss was $15.0 million on a reported basis and $9.9 million on an adjusted basis, representing year-over-year improvements of 25% and 32%, respectively 2024 Financial Outlook Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to FY 2023 Adjusted gross margin is now expected to be between 72.0% to 72.5%, compared to 72.2% in FY 2023 Adjusted operating loss guidance remains unchanged and is expected to be between $45M and $50M, compared to $55.9 million in FY 2023 "We delivered another quarter of strong forward-looking indicators and continued bottom-line improvements in Q2, despite facing macro-related headwinds in BioPharma and EMEA which offset outsized performance in the U.S.," said Jurgi Camblong, PhD.

  • 1(current)

What type of business is SOPHiA GENETICS SA?

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

What sector is SOPHiA GENETICS SA in?

SOPHiA GENETICS SA is in the Healthcare sector

What industry is SOPHiA GENETICS SA in?

SOPHiA GENETICS SA is in the Health Information Services industry

What country is SOPHiA GENETICS SA from?

SOPHiA GENETICS SA is headquartered in Switzerland

When did SOPHiA GENETICS SA go public?

SOPHiA GENETICS SA initial public offering (IPO) was on 23 July 2021

What is SOPHiA GENETICS SA website?

https://www.sophiagenetics.com

Is SOPHiA GENETICS SA in the S&P 500?

No, SOPHiA GENETICS SA is not included in the S&P 500 index

Is SOPHiA GENETICS SA in the NASDAQ 100?

No, SOPHiA GENETICS SA is not included in the NASDAQ 100 index

Is SOPHiA GENETICS SA in the Dow Jones?

No, SOPHiA GENETICS SA is not included in the Dow Jones index

When was SOPHiA GENETICS SA the previous earnings report?

No data

When does SOPHiA GENETICS SA earnings report?

The next expected earnings date for SOPHiA GENETICS SA is 05 March 2025